東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The efficacy of a dopamine D2 agonis...

Davis-McGuire, Lisa.

FindBook

Google Book

Amazon

博客來

The efficacy of a dopamine D2 agonist in treating obesity and obesity-related conditions in rodent models.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The efficacy of a dopamine D2 agonist in treating obesity and obesity-related conditions in rodent models./
作者:	Davis-McGuire, Lisa.
面頁冊數:	282 p.
附註:	Source: Dissertation Abstracts International, Volume: 66-11, Section: B, page: 5927.
Contained By:	Dissertation Abstracts International66-11B.
標題:	Chemistry, Biochemistry. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3197135
ISBN:	9780542429477

The efficacy of a dopamine D2 agonist in treating obesity and obesity-related conditions in rodent models.
Davis-McGuire, Lisa.

The efficacy of a dopamine D2 agonist in treating obesity and obesity-related conditions in rodent models. - 282 p.

Source: Dissertation Abstracts International, Volume: 66-11, Section: B, page: 5927.

Thesis (Ph.D.)--The Johns Hopkins University, 2006.

The primary goal of this study was to determine the effectiveness of the dopamine D2 agonist, bromocriptine, in reversing the central (reward deficiency), and the peripheral (body composition and metabolic) defects of obesity. To test its effectiveness, and elucidate its mechanism of action (MOA), we performed a randomized controlled experiment examining two genetic models and one environmental model of obesity: (fa/fa) Zucker rats and ob/ob mice; and a rat model of diet-induced obesity (DIO).

ISBN: 9780542429477Subjects--Topical Terms:

1017722
Chemistry, Biochemistry.

The efficacy of a dopamine D2 agonist in treating obesity and obesity-related conditions in rodent models.
LDR:03060nmm 2200325 4500 001 1831806
005 20070529074723.5
008 130610s2006 eng d
020 $a 9780542429477
035 $a (UnM)AAI3197135
035 $a AAI3197135
040 $a UnM $c UnM
100 1 $a Davis-McGuire, Lisa. $3 1920570
245 1 4 $a The efficacy of a dopamine D2 agonist in treating obesity and obesity-related conditions in rodent models.
300 $a 282 p.
500 $a Source: Dissertation Abstracts International, Volume: 66-11, Section: B, page: 5927.
500 $a Adviser: Lawrence Cheskin.
502 $a Thesis (Ph.D.)--The Johns Hopkins University, 2006.
520 $a The primary goal of this study was to determine the effectiveness of the dopamine D2 agonist, bromocriptine, in reversing the central (reward deficiency), and the peripheral (body composition and metabolic) defects of obesity. To test its effectiveness, and elucidate its mechanism of action (MOA), we performed a randomized controlled experiment examining two genetic models and one environmental model of obesity: (fa/fa) Zucker rats and ob/ob mice; and a rat model of diet-induced obesity (DIO).
520 $a Bromocriptine significantly improved the central (reward deficiency) defects in genetically obese and diet-induced obese (DIO) rodents. Food intake was significantly reduced compared to pre-treatment measurements each week of the 4-week treatment phase in Zucker and DIO rats. Among ob mice, there was a trend toward reduced food intake during weeks 1 and 2. Locomotor activity was significantly increased during the 12-hr (dark) phase and 22-hr phase in bromocriptine-treated Zucker and DIO rats compared to fatty controls.
520 $a In the periphery, bromocriptine significantly reduced epididymal fat pads in DIO rats and ob mice compared to controls. Hepatic lipids were significantly reduced in all models of obesity compared with fatty controls. Manganese superoxide dismutase (MnSOD), an antioxidant enzyme, and blood glucose, were significantly increased in treated Zucker rats compared with fatty controls.
520 $a Compared with controls, we observed significant increases in dopamine D2 receptor binding in bromocriptine-treated Zucker rats and ob/ob mice in both striatal and lateral hypothalamic regions. Among genetically obese rodents, increases in D2 receptor binding correlated inversely with food intake, body fat, and hepatic fat and positively with locomotor activity and MnSOD. We found significant increases in dopamine transporter (DAT) in the nucleus accumbens (NA) shell in DIO rats, but no differences in DRD2 binding, indicating a likely different MOA by which bromocriptine exerts its antiobesity effects in genetically-obese and diet-induced obese rodents.
590 $a School code: 0098.
650 4 $a Chemistry, Biochemistry. $3 1017722
650 4 $a Health Sciences, Medicine and Surgery. $3 1017756
650 4 $a Health Sciences, Public Health. $3 1017659
690 $a 0487
690 $a 0564
690 $a 0573
710 2 0 $a The Johns Hopkins University. $3 1017431
773 0 $t Dissertation Abstracts International $g 66-11B.
790 1 0 $a Cheskin, Lawrence, $e advisor
790 $a 0098
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3197135